Mon panier

Recombinant Monoclonal Anti-CD45RO Antibody, Mouse (4C8)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
HGS-S249-20ul
$130.00
HGS-S249-100ul
$440.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Background

    Recombinant Monoclonal Anti-CD45RO Antibody, Mouse (4C8) is a CD45RO primary antibody for IHC application. CD45RO (UCHL1, ubiquitin carboxyl terminal esterase L1) is the shortest isoform of a receptor-type protein tyrosine phosphatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apoptosis.

  • Product Specifications

    Host Species
    Mouse
    Isotype
    Mouse IgG
    Clone
    4C8
    Application
    IHC-P
    Dilution Ratio
    1: 200 - 1: 1000
    Form
    Liquid
    Clonality
    Monoclonal
    Reactivity
    Human
    Synonyms
    CD45RO
    Concentration
    0.9~1.1 mg/ml
    Specificity
    React with CD45RO protein on the membrane of target cell/tissue
    Purification Tech
    Protein A
    Preservation
    Tris buffer, 1% BSA
  • Experiment Protocol

    LEICA Experiment Protocol

  • Storage

    Shipped at 4°C, Blue Ice. Store at +4°C for short term (1-2 weeks). Store at -20°C for long term.
    Avoid freeze / thaw cycle. Upon delivery aliquot. The shelf life is 30 days from the date of opening.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Sample Staining Data

     CD45RO SAMPLE STAINING DATA
  •  CD45RO SAMPLE STAINING DATA
  •  CD45RO SAMPLE STAINING DATA

    Immunohistochemical analysis of paraffin embedded human cancer tissue labelled with HGS-S249 at 1/500 dilution.
    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Avis des utilisateurs
Publier un commentaire

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Leukocyte common antigen

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    4 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs